Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study

BACKGROUND: Shorter duration of infusion of monoclonal antibody treatments may reduce treatment burden and improve healthcare resource utilization. METHODS: This phase II study recruited Japanese patients with previously untreated CD20+ B-cell non-Hodgkin lymphoma. Patients received intravenous obin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Jpn J Clin Oncol
Autors principals: Ohmachi, Ken, Ando, Kiyoshi, Kinoshita, Tomohiro, Kumagai, Kyoya, Hatake, Kiyohiko, Ishikawa, Takayuki, Teshima, Takanori, Kato, Koji, Izutsu, Koji, Ueda, Eisuke, Nakai, Kiyohiko, Kuriki, Hiroshi, Tobinai, Kensei
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6057540/
https://ncbi.nlm.nih.gov/pubmed/30060000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyy087
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars